{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:26:54Z","timestamp":1761989214658},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007268","name":"Washington University in St. Louis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Addictive Behaviors"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.addbeh.2018.05.015","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T12:22:19Z","timestamp":1526991739000},"page":"11-16","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Oral and non-oral routes of administration among prescription opioid users: Pathways, decision-making and directionality"],"prefix":"10.1016","volume":"86","author":[{"given":"Theodore J.","family":"Cicero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addbeh.2018.05.015_bb0005","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1360-0443.2012.03803.x","article-title":"The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users","volume":"107","author":"Bruneau","year":"2012","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.addbeh.2018.05.015_bb0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/pds.4287","article-title":"Important statistical considerations in the evaluation of post-market studies to assess whether opioids with abuse-deterrent properties result in reduced abuse in the community","volume":"27","author":"By","year":"2018","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"3","key":"10.1016\/j.addbeh.2018.05.015_bb0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.drugalcdep.2012.11.018","article-title":"National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009","volume":"131","author":"Calcaterra","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"43","key":"10.1016\/j.addbeh.2018.05.015_bb0020","first-page":"1487","article-title":"Vital signs: overdoses of prescription opioid pain relievers-United States, 1999\u20132008","volume":"60","author":"Centers for Disease Control and Prevention(CDC)","year":"2011","journal-title":"MMWR"},{"key":"10.1016\/j.addbeh.2018.05.015_bb0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1526-4637.2006.00259.x","article-title":"The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS\u00ae)","volume":"8","author":"Cicero","year":"2007","journal-title":"PainMed"},{"issue":"5","key":"10.1016\/j.addbeh.2018.05.015_bb0030","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","article-title":"Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from OxyContin","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1016\/j.addbeh.2018.05.015_bb0035","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.pain.2013.07.025","article-title":"Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States","volume":"154","author":"Cicero","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.addbeh.2018.05.015_bb0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.addbeh.2018.05.015_bb0045","unstructured":"U.S. Food and Drug Administration. FDA briefing document: postmarketing safety issues related to reformulated Opana ER. 2017.: https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee\/UCM545760.pdf. Accessed August 30, 2017, (Available at)"},{"issue":"1","key":"10.1016\/j.addbeh.2018.05.015_bb0050","first-page":"85","article-title":"Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations","volume":"128","author":"Gasior","year":"2016"},{"key":"10.1016\/j.addbeh.2018.05.015_bb0055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.drugalcdep.2017.01.039","article-title":"Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration","volume":"175","author":"Green","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.addbeh.2018.05.015_bb0060","series-title":"Report of the international narcotics control board for","volume":"2009","author":"International Narcotics Control Board","year":"2008"},{"issue":"4","key":"10.1016\/j.addbeh.2018.05.015_bb0065","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/00952990.2011.569623","article-title":"Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions","volume":"37","author":"Katz","year":"2011","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.addbeh.2018.05.015_bb0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: Implications for treatment","volume":"1","author":"Kosten","year":"2002","journal-title":"Science & Practice Perspectives"},{"issue":"1","key":"10.1016\/j.addbeh.2018.05.015_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsat.2014.07.002","article-title":"Injection and sexual HIV\/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City","volume":"48","author":"Mateu-Gelabert","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.addbeh.2018.05.015_bb0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1465-3362.2011.00291.x","article-title":"The prescription drug epidemic in the United States: a perfect storm","volume":"30","author":"Maxwell","year":"2011","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.addbeh.2018.05.015_bb0085","first-page":"2016-Q3","article-title":"Comparing Prescription Opioids, Methadone, and Heroin Endorsement Rates from the Treatment Episode Data Set to the RADARS\u00ae System Treatment Center Programs","author":"McDaniel","year":"2016","journal-title":"RADARS\u00ae System Technical Report"},{"issue":"1","key":"10.1016\/j.addbeh.2018.05.015_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2014.08.004","article-title":"Prescription drug abuse: from epidemiology to public policy","volume":"48","author":"McHugh","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.addbeh.2018.05.015_bb0095","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/pop.2013.0098","article-title":"Prescription opioid abuse: a literature review of the clinical and economic burden in the United States","volume":"17","author":"Meyer","year":"2014","journal-title":"Population Health Management"},{"issue":"4","key":"10.1016\/j.addbeh.2018.05.015_bb0100","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1476-5381.2011.01335.x","article-title":"Analysis of opioid efficacy, tolerance, addition and dependence from cell culture to human","volume":"164","author":"Morgan","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.addbeh.2018.05.015_bb0105","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.jpain.2013.04.011","article-title":"Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010","volume":"14","author":"Severtson","year":"2013","journal-title":"The Journal of Pain"},{"key":"10.1016\/j.addbeh.2018.05.015_bb0110","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/10550887.2011.609805","article-title":"Alternate routes of administration and risk for HIV among prescription opioid abusers","volume":"30","author":"Surratt","year":"2011","journal-title":"Journal of Addictive Diseases"},{"issue":"2","key":"10.1016\/j.addbeh.2018.05.015_bb0115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.emc.2015.11.002","article-title":"The Opioid Epidemic in the United States","volume":"34","author":"Wilkerson","year":"2016","journal-title":"Emergency Medicine Clinics of North America"}],"container-title":["Addictive Behaviors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460318305276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306460318305276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T11:00:00Z","timestamp":1534849200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306460318305276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":23,"alternative-id":["S0306460318305276"],"URL":"https:\/\/doi.org\/10.1016\/j.addbeh.2018.05.015","relation":{},"ISSN":["0306-4603"],"issn-type":[{"value":"0306-4603","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral and non-oral routes of administration among prescription opioid users: Pathways, decision-making and directionality","name":"articletitle","label":"Article Title"},{"value":"Addictive Behaviors","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addbeh.2018.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}